RecruitingNCT05178277

Czech AATD Registry

Czech Alpha-1 Antitrypsin Deficiency Registry, the National Observational Study.


Sponsor

Thomayer University Hospital

Enrollment

300 participants

Start Date

Jan 1, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

Alpha-1-antitrypsin deficiency is the most common congenital disease of the respiratory system, leading to early pulmonary emphysema or bronchiectasis. Pulmonary involvement significantly accelerates active cigarette smoking. Patients with alpha-1-antitrypsin deficiency may also have liver cirrhosis, vasculitis, skin or intestinal disorders. The AATD Registry is a non-interventional multicenter retrospective prospective longitudinal follow-up of patients with alpha-1-antitrypsin deficiency. The aim of the AATD National Registry is to collect and analyze clinical data in patients with alpha-1 antitrypsin deficiency.


Eligibility

Inclusion Criteria1

  • Patients with alpha-1-antitrypsin deficiency

Exclusion Criteria1

  • Patient disagreement with inclusion in the study

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Thomayer university hospital

Prague, Czech Republic, Czechia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05178277


Related Trials